[휴온스바이오파마 IPO] ④중국 상륙한 ‘휴톡스’...매출 저변 확대

Huons Biopharm's Q2 2026 entry into China's $20 billion botulinum toxin market demonstrates how Korean biotech firms are capturing high-growth aesthetic markets as consumer demand rises with China's GDP crossing $12,000 per capita. The IPO-preparing company's proven track record—with seven years of domestic success and revenue averaging ₩404 billion annually—positions it to leverage IPO capital for rapid portfolio expansion and competitive scaling against established leaders.